Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis.

A B M Kamrul-HasanDeep DuttaLakshmi NagendraMeha SharmaShinjan PatraSaptarshi Bhattacharya

Published in: Medicine (2024)

Anagliptin positively affects glucose control and is safe for managing T2D. Its low-density lipoprotein cholesterol-lowering effect warrants further investigation.

Keyphrases

type diabetes
glycemic control
blood glucose
cardiovascular disease
insulin resistance
blood pressure
metabolic syndrome